MODULATION OF HEPATITIS B VIRUS CCCDNA TRANSCRIPTION

摘要

The present disclosure pertains to the discovery of a new family of "first in class" small molecular inhibitors of hepatitis B virus (HBV) covalently closed circular (ccc) DNA for use as therapeutics in the management of chronic HBV. Provided are agents that provide epigenetic modification of the cccDNA, histone modifying agent, and inhibitors of histone deacetylace activity that in turn modulate HBV cccDNA, which has never been achieved with a pharmacological agent. Also provided are methods for modulating HBV cccDNA, for treating or preventing HBV in a subject, and for modulating cccDNA transcription of hepatitis B in a subject.